Clinical Trial Update: A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immune response of an unadjuvanted RSV maternal vaccine in healthy non-pregnant females aged 9-49; study completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV maternal vaccine (unadjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2023-04-07